Dechert Advises Biota Pharmaceuticals in Acquisition of Anaconda Pharma

Biota Pharmaceuticals, an Atlanta, Georgia based company, announced last week that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, France. Anaconda Pharma's lead candidate is AP611074, a patented direct-acting antiviral currently in the states of development used for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis (RRP), both of which are caused by human papillomavirus (HPV) types 6 and 11. Anaconda Pharma has successfully completed a Phase 2a clinical trial of AP611074 5% gel demonstrating biological activity with a significant reduction in the surface area of condyloma while exhibiting favorable local skin tolerability.

Dechert LLP is acting as legal advisor to Biota Pharmaceuticals. New York based partner David Rosenthal led the Dechert team with assistance from partner Ermine Bolot, and associates Aymeric Gibon and Magali Stuber (Paris) regarding corporate aspects; and partner Bruno Leroy and associate Damien Fenard regarding tax aspects.

Read the release in French (PDF): "Dechert conseille Biota Pharmaceuticals dans le cadre de l’acquisition d’Anaconda Pharma."

About Dechert

Dechert is a global specialist law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.